Pioglitazone prevents tau oligomerization.

@article{Hamano2016PioglitazonePT,
  title={Pioglitazone prevents tau oligomerization.},
  author={Tadanori Hamano and Norimichi Shirafuji and Chiemi Makino and S. C. Yen and Nicholas M. Kanaan and Asako Ueno and Jinya Suzuki and Masamichi Ikawa and Akiko Matsunaga and Osamu Yamamura and Masaru Kuriyama and Yasunari Nakamoto},
  journal={Biochemical and biophysical research communications},
  year={2016},
  volume={478 3},
  pages={
          1035-42
        }
}
Tau aggregation and amyloid β protein (Aβ) deposition are the main causes of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor γ (PPARγ) activation modulates Aβ production. To test whether the PPARγ agonist pioglitazone (PIO) is also effective in preventing tau aggregation in AD, we used a cellular model in which wild-type tau protein (4R0N) is overexpressed (M1C cells) (Hamano et al., 2012) as well as primary neuronal cultures. PIO reduced both phosphorylated and total tau… CONTINUE READING